2 Stocks to Buy Hand Over Fist in October
Nutex Health and Elevance Health may be underpriced, despite their share growth this year.
Stock Taper 
ELV
$400.94
▼ DOWN 0.83% (-3.37)
KEY STATISTICS
Market Cap$87.07 B
52w High$436.24
52w Low$274.84
Dividend Yield1.84%
FrequencyQuarterly
P/E13.64
Volume782.71K
Shares Out.216.87M
COMPANY
LEADERSHIP
CHIEF EXECUTIVE
Gail Koziara Boudreaux
COMPENSATION 2026
Salary$555,667
Stock Awards$792,000
Incentive Plan Pay$0
All Other Comp.$125,953
Total$2,440,530
ABOUT
SECTOR
Healthcare
WENT PUBLIC
October 30, 2001
METHOD OF GOING PUBLIC
N/A
FULL TIME EMPLOYEES
96,615
PRICE TARGET
Target High$498.00
Target Low$391.00
Target Median$457.50
Target Consensus$444.81
UPCOMING EARNINGS
DateOct 21, 2026
DayWednesday
Rev. Est.$49.32B
OCT
21
WED
SPLIT RECORD
| DATE | TYPE | RATIO |
|---|---|---|
| 2005-06-01 | Forward | 2:1 |
ETFS HOLDING THIS STOCK
ETFS HOLDING
534
LISTED HERE
10
RANKED BY POSITION SIZE
INSTITUTIONAL OWNERSHIP
SHARES OWNED
48.25%
HOLDERS
2,312
TOP 8 OF 2,312 · RANKED BY POSITION SIZE
PRICE
$400.94 ▼ DOWN 0.83% (−$3.37)About Elevance Health Inc.
https://www.elevancehealth.com ↗Elevance Health Inc., formerly Anthem, Inc., is a health benefits company serving 118 million people with medical, digital, pharmacy, behavioral, and care solutions to support healthier lives nationwide.
INDUSTRY
Medical - Healthcare Plans
A SERVICE ELEVANCE HEALTH INC. IS KNOWN FOR
Health Insurance Plans
Elevance Health provides diverse health insurance plans, including HMOs, PPOs, Medicare, and Medicaid, through affiliates like Anthem Blue Cross and Blue Shield, serving over 47 million members with medical, pharmaceutical, dental, and behavioral ...
Elevance Health in 2025
SENTIMENT: − NEGATIVE
EARNINGS · JULY 2025
Elevance Health Cuts Full-Year 2025 Profit Outlook, Citing Soaring Medical Costs
In its Q2 2025 earnings report, Elevance Health significantly lowered its full-year profit guidance, attributing the revision to unexpectedly high medical costs and utilization rates, particularly within its Medicaid and Affordable Care Act (ACA) plan segments. [1, 7, 10] This announcement signaled to investors that rising healthcare expenses were more persistent than anticipated, creating pressure on the company's profitability.
MARKET EXIT · SEPTEMBER 2025 · ANNOUNCED
Elevance Health to Exit Standalone Medicare Part D Market and Scale Back on Underperforming Medicare Advantage Plans
Elevance Health announced a significant strategic shift in its Medicare business, planning to exit the standalone Medicare Part D market entirely and withdraw from certain underperforming Medicare Advantage plans and counties. This move is intended to allow the company to concentrate its resources on more profitable and stronger product lines, specifically Medicare Advantage HMOs and dual-special needs plans (D-SNPs).
Latest News
EARLIER COVERAGE
ELV or DHR: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical Services sector have probably already heard of Elevance Health (ELV) and Danaher (DHR). But which of these two stocks is more attractive to value investors?
Are Medical Stocks Lagging Elevance Health, Inc. (ELV) This Year?
Here is how Elevance Health (ELV) and American Well Corporation (AMWL) have performed compared to their sector so far this year.
Elevance Health's Affiliated 2027 Medicare Advantage Plans Advance Stability, Choice and More Coordinated Support
INDIANAPOLIS--(BUSINESS WIRE)--Elevance Health (NYSE: ELV) announced today that its affiliated health plans will offer 2027 Medicare Advantage plans designed to help members navigate healthcare more confidently through meaningful choice, simpler benefit experiences and personalized support that reflects individual health needs. As members evaluate Medicare coverage for 2027, many want to understand their benefits, connect to care, manage healthcare costs and know where to turn for support throu.
RATINGS SNAPSHOT
Overall rating: A-
Discounted Cash Flow5
Return On Equity4
Return On Assets5
Debt To Equity1
Price To Earnings3
Price To Book3
Overall Score4
MOST RECENT ANALYST GRADES
GRADE SUMMARY
BUY 7
OVERWEIGHT 4
OUTPERFORM 3
MARKET PERFORM 1
SECTOR PERFORM 1
NEUTRAL 1
EQUAL WEIGHT 1
IN LINE 1
19 GRADES IN THE LAST 12 MONTHS
SECTORS PEERS
| PEER | PRICE | |
|---|---|---|
 UNH | $372.81 | COMPARE |
 CVS | $88.30 | COMPARE |
 GSK | $46.59 | COMPARE |
 REGN | $732.91 | COMPARE |
 CI | $280.70 | COMPARE |
 COR | $314.08 | COMPARE |
 BDX | $181.37 | COMPARE |
 HUM | $387.08 | COMPARE |
TRADES BY CONGRESS
SENATE TRADES
Alan Armstrong
Purchase
2026-03-27
HOUSE TRADES
Ro Khanna
Sale
2026-01-29
SENATE TRADES
Markwayne Mullin
Purchase
2025-12-29
John Fetterman
Sale
2025-09-19
INSIDER TRADES
★
OFFICER: EVP & CFO
Kaye Mark
Sale · 4.2K shares
2026-10-02
★
OFFICER: EVP & CFO
Kaye Mark
Purchase · 2.6K shares
2026-10-02
★
OFFICER: EVP & CHIEF LEGAL OFFICER
Wessling Erin M
Sale · 255 shares
2026-09-03
★
OFFICER: EVP & CHIEF HR OFFICER
Craig Ryan R
Sale · 144 shares
2026-09-02